Product Image

Contributor Information

  • Name Thorbald Van Hall
  • Institute Leiden University and Leiden University Medical Center; Stichting Oncode Institute

Tool Details

  • Tool name: RMA.Trh4 Db KO cells
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: RMA
  • Organism: Mouse
  • Tissue: Lymphatic Tissue
  • Cancer type: Mouse Leukemia
  • Disease: Cancer
  • Description: This cell line overexpresses the ER-resident ceramide synthase Trh4 (transduced by CRISPR) and lacks the H2-Db gene. It serves as a control in helping to understanding T-cell recognition of the Trh4-derived peptide presented by the MHC class I molecule H2-Db. This peptide-epitope is a prototypic example of a neo-antigen selectively presented by cells with processing defects in the classical MHC class I (MHC-I) pathway. RMA cells have an intact processing pathway and a functional TAP peptide transporter, but overexpress the Trh4 protein and therefore could present the Trh4 peptide. However, no T cell recognition can be observed due to the absence of the MHC class I H2-Db.This population acts as a clear control.
  • Research area: Cancer
  • Additional notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license

  • For Research Use Only

Target Details

Application Details

Handling

  • Format: Frozen
  • Growth medium: Suspension cells in DMEM+8% FCS
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 1

Documentation

  • Available on request

References

  •   Doorduijn et al. 2018. Oncoimmunology. 7(3):e1382793. PMID: 29399388.